跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
瑞普佳 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Agalsidase Alfa Concentrated Solution for Infusion
Approved
生物制品
Agalsidase Alfa Concentrated Solution for Infusion
TAKEDA PHARMACEUTICALS INTERNATIONAL AG IRELAND BRANCH
🇨🇳 National Medical Products Administration
Approval Date
May 19, 2025
Approval ID
888ihlS9yHo
Company
TAKEDA PHARMACEUTICALS INTERNATIONAL AG IRELAND BRANCH
Type
生物制品
Approval Details
Approval Id
888ihlS9yHo
Approval Number
国药准字SJ20200021
Generic Name
阿加糖酶α注射用浓溶液
Generic Name En
Agalsidase Alfa Concentrated Solution for Infusion
Trade Name
瑞普佳
Drug Type
生物制品
Dosage Form
注射剂
Strength
3.5mg（3.5ml）/瓶
Reg Date
2025-05-19
Expired Date
2030-05-18
Company Name
TAKEDA PHARMACEUTICALS INTERNATIONAL AG IRELAND BRANCH
Company Detail Path
/organization/takeda-pharmaceuticals-international-ag-ireland-branch
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
May 19, 2025
Approval ID
888ihlS9yHo
Type
生物制品
Back to NMPA Approvals
